Last reviewed · How we verify
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers
To examine the efficacy of Montelukast as an adjunct to INCS in patients with allergic rhinitis.
Details
| Lead sponsor | Assiut University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | UNKNOWN |
| Enrolment | 60 |
| Start date | 2022-10 |
| Completion | 2024-10 |
Conditions
- Allergic Rhinitis
Interventions
- Montelukast Oral Tablet
Primary outcomes
- Nasal symptoms — 3 monthes
Participants will be asked to score five Sino-nasal symptoms (nasal congestion/obstruction, anterior rhinorrhea, posterior rhinorrhea, loss of smell, and facial pain) from 0 to 4. This score will be assessed at the screening and follow-up visits at 12 weeks. The total five-symptom score (T5SS) was obtained with the sum of the individual symptoms (0-20). - laboratory findings — 3 months
Evaluation of inflammatory markers levels (TNF-α, IL-6, IL-12) in inpatient blood At 0 point premedication (pre-medication) At 1 point post medication after 12 weeks (3 months) - Quality of life symptoms — 3 monthes
Subjects will complete a validated questionnaire related to the general quality of life in patients with allergic rhinitis; this questionnaire records patients' symptoms The patients receive a rhino-conjunctivitis quality of life questionnaire. This questionnaire records domains like patient activities, sleep, ......and emotional problems on an 0-x ordinal scale.